PURPOSE: To identify risk factors associated with outcome in children with metastatic rhabdomyosarcoma in a large cohort of patients PATIENTS AND METHODS: Pooled data were obtained from 788 patients treated in nine studies performed by European and American cooperative groups. Clinical factors, including age, histology, site of primary, and site(s) and number of sites of metastatic disease, were correlated with event-free survival (EFS) and overall survival (OS). RESULTS:Seven hundred eighty-eight patients were eligible for analysis. The 3-year OS and EFS were 34% (SE, 1.7) and 27% (SE, 1.6), respectively. By univariate analysis, 3-year EFS was significantly and adversely influenced by age, alveolar histology, location of primary tumor in unfavorable site (defined as extremity and "other" sites), presence of three or more sites of metastatic disease, and the presence of bone or bone marrow involvement. By multivariate analysis, EFS was strongly correlated to all factors except histology. Relative risks were 1.6 for age younger than 1 year or at least 10 years, 1.4 for unfavorable site of primary tumor, 1.4 for bone or bone marrow involvement, 1.4 for three or more metastatic sites. EFS was 50% for patients without any of these four adverse factors and was respectively 42%, 18%, 12%, and 5% in patients with one, two, three, or four factors (P < .0001). CONCLUSION: This analysis identified subsets of patients with metastatic rhabdomyosarcoma with different outcomes to current therapy and offers a strategy to define patient candidates for experimental approaches to treatment.
RCT Entities:
PURPOSE: To identify risk factors associated with outcome in children with metastatic rhabdomyosarcoma in a large cohort of patientsPATIENTS AND METHODS: Pooled data were obtained from 788 patients treated in nine studies performed by European and American cooperative groups. Clinical factors, including age, histology, site of primary, and site(s) and number of sites of metastatic disease, were correlated with event-free survival (EFS) and overall survival (OS). RESULTS: Seven hundred eighty-eight patients were eligible for analysis. The 3-year OS and EFS were 34% (SE, 1.7) and 27% (SE, 1.6), respectively. By univariate analysis, 3-year EFS was significantly and adversely influenced by age, alveolar histology, location of primary tumor in unfavorable site (defined as extremity and "other" sites), presence of three or more sites of metastatic disease, and the presence of bone or bone marrow involvement. By multivariate analysis, EFS was strongly correlated to all factors except histology. Relative risks were 1.6 for age younger than 1 year or at least 10 years, 1.4 for unfavorable site of primary tumor, 1.4 for bone or bone marrow involvement, 1.4 for three or more metastatic sites. EFS was 50% for patients without any of these four adverse factors and was respectively 42%, 18%, 12%, and 5% in patients with one, two, three, or four factors (P < .0001). CONCLUSION: This analysis identified subsets of patients with metastatic rhabdomyosarcoma with different outcomes to current therapy and offers a strategy to define patient candidates for experimental approaches to treatment.
Authors: Alberto S Pappo; Elizabeth Lyden; Phillip Breitfeld; Sarah S Donaldson; Eugene Wiener; David Parham; Kristine R Crews; Peter Houghton; William H Meyer Journal: J Clin Oncol Date: 2007-02-01 Impact factor: 44.544
Authors: Joanne J Lager; Elizabeth R Lyden; James R Anderson; Alberto S Pappo; William H Meyer; Philip P Breitfeld Journal: J Clin Oncol Date: 2006-07-20 Impact factor: 44.544
Authors: H M Maurer; E A Gehan; M Beltangady; W Crist; P S Dickman; S S Donaldson; C Fryer; D Hammond; D M Hays; J Herrmann Journal: Cancer Date: 1993-03-01 Impact factor: 6.860
Authors: Simone Hettmer; Zhizhong Li; Andrew N Billin; Frederic G Barr; D D W Cornelison; Alan R Ehrlich; Denis C Guttridge; Andrea Hayes-Jordan; Lee J Helman; Peter J Houghton; Javed Khan; David M Langenau; Corinne M Linardic; Ranadip Pal; Terence A Partridge; Grace K Pavlath; Rossella Rota; Beat W Schäfer; Janet Shipley; Bruce Stillman; Leonard H Wexler; Amy J Wagers; Charles Keller Journal: Cold Spring Harb Perspect Med Date: 2014-11-03 Impact factor: 6.915
Authors: Joseph G Pressey; Marilyn C Haas; Christine S Pressey; Virginia M Kelly; Jacqueline N Parker; G Yancey Gillespie; Gregory K Friedman Journal: Pediatr Blood Cancer Date: 2012-03-09 Impact factor: 3.167
Authors: Catherine J Drummond; Jason A Hanna; Matthew R Garcia; Daniel J Devine; Alana J Heyrana; David Finkelstein; Jerold E Rehg; Mark E Hatley Journal: Cancer Cell Date: 2018-01-08 Impact factor: 31.743
Authors: Sheri L Spunt; Sara O Vargas; Cheryl M Coffin; Stephen X Skapek; David M Parham; Joan Darling; Douglas S Hawkins; Charles Keller Journal: Cancer Date: 2011-10-17 Impact factor: 6.860
Authors: Peter Brader; Sara J Abramson; Anita P Price; Nicole M Ishill; Zabor C Emily; Chaya S Moskowitz; Michael P La Quaglia; Michelle S Ginsberg Journal: J Pediatr Surg Date: 2011-04 Impact factor: 2.545
Authors: Lama Jurdy; Johanus H M Merks; Bradly R Pieters; Maarten P Mourits; Roel J H M Kloos; Simone D Strackee; Peerooz Saeed Journal: Saudi J Ophthalmol Date: 2013-07
Authors: Sara M Federico; Sheri L Spunt; Matthew J Krasin; Catherine A Billup; Jianrong Wu; Barry Shulkin; Gerald Mandell; M Beth McCarville Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Suman Malempati; Brenda J Weigel; Yueh-Yun Chi; Jing Tian; James R Anderson; David M Parham; Lisa A Teot; David A Rodeberg; Torunn I Yock; Barry L Shulkin; Sheri L Spunt; William H Meyer; Douglas S Hawkins Journal: Cancer Date: 2018-10-23 Impact factor: 6.860